Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

Expert opinion on pharmacotherapy - 1 Apr 2017

Turner Megan C, Rossfeld Kara, Salama April K S, Tyler Douglas, Beasley Georgia

Abstract excerpt

INTRODUCTION: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Piperidines

Share to Proto-Oncogene Proteins c-kit

Share to Pyridines

Share to Sulfonamides

Share to Thiazoles

Source

Identifiers

PMID: 28277830
DOI: 10.1080/14656566.2017.1299710

Genes

BRAF
KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?PMID 28277830Read ↗

The discovery and development of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

An overview of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

Binimetinib for the treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.Semantic proximity Read ↗

Development of encorafenib for BRAF-mutated advanced melanoma.Semantic proximity Read ↗

[Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].Semantic proximity Read ↗

A review of binimetinib for the treatment of mutant cutaneous melanoma.Semantic proximity Read ↗

Encorafenib and Binimetinib: First Global Approvals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.